28. Bernstein SH, Unger JM, LeBlanc M et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow- Patients and methods: The primary objective was to assess dose-limiting toxicities (DLTs) during cycle 1 for each regimen, from which the maximum tolerated dose (MTD) was determined. Patients received once daily oral afatinib 20, 30, 40 or 50 mg in 21-day cycles (3 + 3 design).
introduction
Novel targeted therapies that can be used in combination with standard chemotherapy regimens offer the potential to improve outcomes in patients with advanced cancer. Therapies targeted to a specific signaling pathway are more selective, with the potential of reducing side-effects compared with broad-acting chemotherapy agents.
One of the signaling pathways often dysregulated in malignant epithelial cells is the ErbB family of receptor tyrosine kinases and their associated ligands, which comprises four structurally related transmembrane receptor tyrosine kinases: epidermal growth factor receptor (EGFR; ErbB1), human EGFR 2 (HER2; ErbB2), ErbB3 and ErbB4 [1] [2] [3] .
Afatinib (BIBW 2992), a highly selective and irreversible blocker of the ErbB family, binds covalently and irreversibly to the intracellular tyrosine kinase domain, preventing intracellular signaling [4, 5] . By targeting the ErbB family receptors, afatinib blocks a wide spectrum of cancer-relevant, ErbB-driven pathways, and thereby has the potential to be effective against a range of ErbB-dependent tumor types [3, 6] .
Preclinically, xenograft models have shown that afatinib has a broad spectrum of anticancer activity in vivo [4] . In the clinical setting, phase I studies have shown that afatinib monotherapy is well tolerated and established the maximum tolerated dose (MTD) of afatinib as 40 mg, with diarrhea and skin rash constituting the main dose-limiting toxicities (DLTs) [7] [8] [9] [10] .
Preliminary antitumor activity data from phase I monotherapy studies also indicate that patients with advanced solid tumors can benefit from treatment with afatinib in 43% of patients demonstrating stable disease (SD) [8] .
Combinations of both cisplatin (75 mg/m 2 ) plus paclitaxel (175 mg/m 2 ), and cisplatin (100 mg/m 2 ) plus 5-fluorouracil (5-FU; 1000 mg/m 2 ) are frequently used in the treatment of advanced cancer, demonstrating improved response rates compared with monotherapy. The efficacy of platinum-based chemotherapy, however, does appear to have reached a plateau, suggesting the need for incorporating targeted therapies. With similar survival rates reported in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN), both chemotherapy regimens have the potential to show enhanced efficacy following the inclusion of targeted agents [11] . Moreover, the combination of afatinib with standard chemotherapies such as paclitaxel or docetaxel appears to be feasible, from previous pre-clinical [4] and phase I studies [12] [13] [14] . In light of this combined evidence, the safety, preliminary antitumor activity and pharmacokinetics of afatinib in combination with either cisplatin and paclitaxel (regimen A) or cisplatin and 5-FU (regimen B) were assessed in patients with advanced solid tumors.
patients and methods

study design
This multicenter, open-label, phase Ib, dose-escalation study (NCT00716417) was conducted between August 2008 and December 2010 in three sites across Belgium. Patients were not randomly assigned, but sequentially allocated to each regimen and the dose cohorts according to their date of entry into the study.
A standard 3 + 3, phase I methodology was employed for each regimen, with three patients being treated at the initial dose. If no DLT was observed within the first cycle in any of these patients, then the dose was escalated and three more patients were treated. If one patient experienced a DLT, another three patients were treated at the same dose. In the event that two or more patients experienced a DLT, dose escalation was stopped. The MTD of afatinib was defined as the highest dose at which one out of six patients experienced a DLT during the first treatment cycle.
For regimen A, the starting dose of afatinib was escalated to determine the MTD in combination with cisplatin and paclitaxel (Taxol; Supplementary S1 available at Annals of oncology online). On day 1 of cycle 1, paclitaxel was intravenously infused over 3 h, followed by an intravenous (i.v.) infusion of cisplatin over 1 h. Afatinib treatment commenced on day 3 of the first cycle and continued daily thereafter for as long as chemotherapy was given. Initially, afatinib 20 mg was combined with a reduced dose of cisplatin For regimen B, the afatinib dose was escalated to determine the MTD in combination with cisplatin and 5-FU (Supplementary S1 available at Annals of oncology online). On day 1 of cycle 1, cisplatin was intravenously infused over 1 h, followed by an IV infusion of 5-FU continuously over 96 h on days 1-4. The treatment with afatinib was commenced on day 5 of the first cycle and continued daily thereafter as long as chemotherapy was given. Initially, reduced doses of both cisplatin reduced to the previous dose level if two patients experienced DLTs (during the first treatment cycle) at a certain dose level. A DLT was defined as an adverse event (AE) occurring during the first chemotherapy cycle (21 days) that was considered to be related to the trial medication and included pre-defined serious hematologic and nonhematologic toxic effects according to Common Terminology Criteria for Adverse Events (CTCAE, version 3). In the event of a DLT, treatment was discontinued for up to 14 days until toxicity had improved to CTCAE grade 1 or baseline CTCAE grade (whichever was higher). For patients recovering within that time, a dose-reduction scheme was followed for subsequent treatment cycles; patients who did not recover within 14 days were taken off study. Patients with either an objective tumor response or the absence of progressive disease (PD) during treatment were eligible to receive further treatment cycles. Chemotherapy was administered for up to six cycles; patients who still showed benefit from treatment were allowed to continue with afatinib monotherapy until tumor progression or undue toxicity.
The trial was carried out in compliance with the protocol and principles laid down in the Declaration of Helsinki (1996 version), in accordance with the International Conference on Harmonization-Good Clinical Practice and in accordance with the applicable regulatory requirements. Patients were also required to provide full written consent.
study population
The eligible patients were adults with a life expectancy of ≥3 months and an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. Patients were required to have cytologically or histologically confirmed non-resectable and/or metastatic cancer, preferably with SCCHN, esophagus, lung or cervix. While not stipulated as an entry criterion, measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) was preferred. Indication for a standard treatment with either cisplatin and paclitaxel or cisplatin and 5-FU was required. Patients with untreated or active brain metastases, active infectious disease or pre-existing interstitial lung disease were excluded from the study.
safety and tolerability assessments
The primary end point of this trial was the determination of the MTD based on DLTs observed with afatinib during the first treatment cycle of each regimen. Safety was evaluated by the assessment of AEs, clinical laboratory tests, vital signs, physical examinations and cardiac function.
antitumor activity assessments
Objective tumor response was assessed according to RECIST version 1.0. Target lesions were assessed and defined as either a complete response (CR), partial response (PR), SD or PD [15] . Baseline tumor assessment was completed within 28 days before the start of treatment. Tumor assessment or restaging was routinely carried out every two cycles.
pharmacokinetic (PK) sampling and data analysis
Plasma concentrations of all components of trial medication were assessed. In regimen A, 6 ml of venous blood was collected at scheduled times before and after paclitaxel infusion on days 1-3 of cycle 1 (absence of afatinib) and cycle 2 ( presence of afatinib). Additional samples for afatinib pharmacokinetics were taken on days 10 and 21 of cycles 1 and 2, and at 1 and 2 h post-dose on day 1 of cycle 2. In regimen B, 6 ml of venous blood was collected at times before and after the start of cisplatin infusion on days 1 and 2, and after the 5-FU infusion on day 5 of cycle 1 (with afatinib) and 2 (without afatinib). Additional samples for afatinib pharmacokinetics were taken on days 10 and 21 of cycles 1 and 2.
PK data were analyzed using WinNonlin® 5.2 (Pharsight, Mountain View, 94041 CA).
statistical analyses
The analyses in this trial were descriptive and exploratory. All patients who received one or more dose of trial medication were included in the treated set, which was used for all analyses of efficacy and safety, and for PK analysis if data from one or more blood sample post-drug administration were available.
results
patient population
The demographics and clinical characteristics of the 47 study participants (26 for regimen A and 21 for regimen B) displayed heterogeneity within both the groups ( Table 1 ). The most common reason for trial discontinuation was PD (73% in regimen A and 57% in regimen B) followed by patient refusal (12% in regimen A and 5% in regimen B), a DLT (4% in regimen A) and other AEs (12% in regimen A and 33% in regimen B). Most patients (96%) completed one or more treatment cycle [median number completed: five (range 0-30) for regimen A; two (range 1-8) for regimen B]. Sixteen patients [13 (50.0%) in regimen A and 3 (14.3%) in regimen B] experienced benefit from treatment and continued on afatinib monotherapy after discontinuation of chemotherapy (≤6 cycles). Dose-escalation schema and corresponding DLT events for regimen A are shown in Figure 1A . As the highest cohort with less than two DLTs having been experienced, the MTD was determined as afatinib 20 mg combined with 175 mg/m² paclitaxel and 75 mg/m² cisplatin. Overall, as part of the regimen A dose-escalation study, five patients (19%) experienced a DLT within cycle 1 (Table 2) , and two patients died as a result of treatment (septic shock, n = 1; atrial fibrillation, acute pulmonary edema and acute respiratory distress syndrome, n = 1).
regimen B: afatinib, cisplatin and 5-FU Dose-escalation schema and corresponding DLT events for regimen B are shown in Figure 1B . As the highest cohort with less than two DLTs having occurred, the MTD was determined as afatinib 30 mg combined with cisplatin 75 or 100 mg/m² and 5-FU 750 mg/m². In total, as part of the regimen B doseescalation study, four patients (19%) experienced a DLT within cycle 1 ( Table 2) .
safety and tolerability
The most frequent AEs overall and by CTCAE grade 3-5 with regimens A and B are shown in Tables 3 and 4 , respectively. Discontinuation due to any AEs occurred in 38% of patients. With regimen A, 35% and 42% of patients had AEs of maximum CTCAE grade 3 and 4, respectively. The most common AE of maximum CTCAE grade 4 was neutropenia (31%).
Three patients (12%) died due to AEs with regimen A; two deaths were deemed to be treatment-related (septic shock, n = 1; atrial fibrillation, acute pulmonary edema and acute respiratory disease syndrome, n = 1). The third patient from regimen A died following a general deterioration of health, but this was not considered to be treatment-related.
Discontinuation due to all AEs occurred in 48% of patients. With regimen B, 52% of the patients had AEs of maximum CTCAE grade 3, 24% of the patients experienced AEs of maximum CTCAE grade 4 and three patients (14%) died due to AEs. None of these deaths were deemed to be treatmentrelated, with two being attributed to general physical health deterioration and one due to malignant neoplasm.
antitumor activity
Of the 26 patients treated in regimen A, five patients (19%) showed an objective tumor response, of which two were a CR (8%; both had SCCHN originating in the tonsil) and three were PRs (12%; patients had either squamous cell carcinoma of the esophagus, adenocarcinoma of the ampulla of Vater or adenocarcinoma of the ovary), with a further two patients experiencing an unconfirmed PR (Supplementary S2 available at Annals of oncology online).
In total, disease control was observed in 54% of patients in regimen A for a median (95% confidence interval) duration of 212 (141-273) days.
Of the 21 patients treated in regimen B, only one patient (5%) showed an objective tumor response (CR), whereas four additional patients displayed an unconfirmed PR (Supplementary S2 available at Annals of oncology online). . A DLT was defined as an adverse event (AE) occurring during the first chemotherapy cycle (21 days) that was considered to be related to the trial medication and included Common Terminology Criteria for Adverse Events (CTCAE, version 3) grade ≥4 neutropenia for >7 days or thrombocytopenia; CTCAE grade ≥3 febrile neutropenia (fever ≥38.5°C) or thrombocytopenia associated with bleeding and requiring transfusion; or all other hematologic toxic effects of CTCAE grade ≥4 or ≥3 leading to an interruption of trial medication for >14 days until recovery to CTCAE grade ≤1 or baseline CTCAE grade (whichever was higher). Additional criteria for DLTs comprised non-hematologic toxic effects of CTCAE grade ≥3 (except for isolated elevated values for CTCAE grade 3 gamma-glutamyl transpeptidase [γ-GT] or controllable diarrhea, nausea, vomiting and rash); CTCAE grade 2 increase in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST); CTCAE grade 2 nausea and vomiting or diarrhea despite supportive care for 7 days; renal or cardiac toxicity of CTCAE grade 2 or all other CTCAE grade ≥2 non-hematologic toxic effects leading to an interruption of trial medication for >14 days until recovery to CTCAE grade 1 or baseline CTCAE grade (whichever was higher). pharmacokinetics Table 5 summarizes key PK parameters for cisplatin, paclitaxel and 5-FU for the MTD cohorts of regimens A and B. PK parameters were comparable for all chemotherapeutics in the presence and absence of afatinib, suggesting no relevant effect of afatinib on the exposure of each of the compounds. Variability in PK parameters was mainly low to moderate for cisplatin and paclitaxel. For comparability, individual maximum plasma concentration (C max ) and area under the curve (AUC) values were corrected for the contribution of the respective cisplatin predose plasma concentrations (due to the long plasma half-life of total platinum). No difference was observed in corrected C max and AUC values, apart from a slight trend (increase by 17% with afatinib) in the C max of patients in regimen A. A high variability was observed for 5-FU and afatinib PK parameters. However, evaluable data were sparse, as several patients had to be excluded from analysis due to incomplete sampling and/or time violations for drug administration and/or plasma sampling (data not shown). original articles Annals of Oncology associated with EGFR (ErbB1) blockade or the chemotherapy backbone used as part of the regimen. Diarrhea was a primary AE in both regimens; incidence of diarrhea was slightly increased (89% and 86% in regimens A and B, respectively), versus 84% in afatinib monotherapy trials, which also identified skin rash, nausea, and vomiting as other prominent AEs. This increased incidence of diarrhea was unexpected, despite the propensity for diarrhea, nausea and vomiting with 5-FU. Paclitaxel is also known to cause diarrhea, as well as neutropenia, while common AEs associated with cisplatin include nausea and vomiting. In this study, incidences of CTCAE grade 3-5 diarrhea and vomiting with afatinib plus cisplatin/paclitaxel (23% and 8%, respectively) or cisplatin/5-FU (19% and 33%, respectively) are higher than previously reported for the chemotherapy regimens (cisplatin/paclitaxel: 1% and 4%-6%; cisplatin/5-FU: 3% and 1%) [11] . Severe diarrhea, if accompanied by severe vomiting, may pose a risk of dehydration and renal failure with these combination regimens. The primary difference between combination therapy during this trial and previous monotherapy trials of afatinib was the high frequency of hematologic AEs. This is most probably attributable to the use of chemotherapeutic agents in the combination regimens; patients treated with platinums, taxanes and 5-FU often experience these hematologic side-effects [16] . In addition, there was an increased incidence of alopecia in regimen A, but not in regimen B. Although the treatment duration with regimen A (median of five cycles) was substantially longer than with regimen B (median of two cycles), it is most likely that the difference is due to the use of paclitaxel in regimen A, known to induce alopecia as a common AE [17] .
Of note, these patients were suffering from advanced malignancies and heavily pretreated with a median (range) time of 2.2 years (0-16) and 2.1 years (0-21) since diagnosis in groups A and B, respectively. AEs observed in this study may be expected for such patients. Overall, proactive and timely treatment of AEs is required to improve the tolerability of these regimens and minimize patient discontinuation. No significant PK interactions were observed between afatinib and 5-FU, paclitaxel and cisplatin in the applied dosing regimens. The slight increase in cisplatin C max in regimen A patients was not observed in regimen B patients and seemed to be a chance finding, although an effect of afatinib cannot be excluded. Available afatinib PK parameters were within the range observed in earlier studies [7, 8, 10, 18] . Based on the limited data, no firm conclusion can be drawn for afatinib.
Although this trial was not designed to confirm efficacy, CRs were observed with both the regimens at an afatinib dose level of 40 and 20 mg. Considering the great variability in diagnosis and concomitant therapy between dose cohorts, definitive conclusions on the optimal dose of afatinib when combined with cisplatin and paclitaxel or cisplatin and 5-FU cannot be made. However, 10 of the 47 patients included in this study were treated for recurrent/metastatic SCCHN, and three of these patients achieved a CR, which in the context of the disease setting, is promising. The potential importance of this is further emphasized by considering that >90% of SCCHN express EGFR (ErbB1) at high levels, which correlates with poor prognosis and reduced survival [19, 20] .
Studies on non-small-cell lung cancer have reported activity with afatinib at monotherapy doses of 40-50 mg/day [21] [22] [23] . Although combination therapy doses were lower in this study, a CR with afatinib 20 mg suggests activity at lower dose levels.
Theoretically, the activity of established afatinib monotherapy and combination therapy doses could be compared in a crossover study. Irrespective of any dose constraints of the combination regimen, achieving efficacy without untoward intolerability is paramount and any treatment that provides a level of antitumor activity in this advanced population with limited drug options deserves consideration.
Afatinib irreversibly blocks signaling by all ErbB receptor kinases. It is, therefore, likely to be more effective than more limited and less selective agents like tyrosine kinase inhibitors and monoclonal antibodies [24] .
SCCHN has been linked with overexpression of not only EGFR (ErbB1), but also HER2 (ErbB2), ErbB3 and ErbB4, suggesting that an agent which targets multiple members of the ErbB family could be more effective and less susceptible to resistance through compensatory signaling [25] .
The MTD was defined as afatinib 20 mg in combination with 75 mg/m 2 cisplatin and 175 mg/m 2 paclitaxel in regimen A, and afatinib 30 mg in combination with 75 mg/m 2 cisplatin and 750 mg/m 2 5-FU in regimen B. Pre-emptive, vigorous management of side-effects (especially diarrhea) is important in order to enhance safety and tolerability with these combinations. Both afatinib combination regimens showed antitumor activity in patients with various tumor types and lines of prior treatment. 
